DoorDash Agrees to Buy Instacart in $17 Billion Grocery Delivery Deal
The DoorDash Instacart acquisition values Instacart at $65 a share, about $17 billion, with closing expected by mid-2028. Terms, timeline and antitrust questions.
Markets
Markets coverage from The Boston Report on stocks, IPOs, earnings and investor sentiment, with plain-language context for the moves. Not investment advice.
U.S. Economy Grew 3.4% in Third Quarter, Beating Forecasts
Q3 2026 GDP rose at a 3.4% annual rate, faster than forecasters expected, while PCE prices rose 2.1%. What drove the growth and what comes next.
Butterfly Network Q3 Revenue Jumps 52% and Company Raises 2026 Outlook
Burlington’s Butterfly Network posted Q3 2026 revenue of $32.6 million, up 52%, a record 73% gross margin and a higher 2026 outlook. The numbers explained.
Philippine Peso Breaks Past 64 per Dollar as Marcos Says ‘Don’t Panic’
The Philippine peso hit ₱64.17 per dollar on Oct. 27 as reserves fell to a three-year low; Marcos said the government has the tools to defend it.
Business Report: Alphabet Sinks as GDP Hits 3.4%, Oct. 29, 2026
Business report October 29, 2026: GDP grows 3.4%, PCE inflation hits 3.6%, Alphabet has its worst day ever, Lilly lifts health care, and Amazon and Intel slide.
Entegris Posts Record $1 Billion Quarter as Chip Demand Lifts Billerica Supplier
Entegris Q3 earnings: Billerica chip-materials supplier posts record $1.006B in sales, up 25%, EPS more than doubles. Charts, segments and Q4 outlook.
Alnylam Q3 Sales Jump 52% to $1.29 Billion on Amvuttra Heart Drug Demand
Alnylam Q3 earnings: product sales rose 52% to $1.29B as Amvuttra hit $1.13B. Charts on revenue, the $1.9B tax benefit, guidance and pipeline.
Alphabet Stock Heads for Worst Day Since 2004 IPO as AI Spending Turns Cash Flow Negative
Alphabet stock fell about 12% after Q3 results showed negative $9.1 billion free cash flow and a search miss. The data, and how Microsoft’s quarter compared.
Biogen Q3 Revenue Jumps 11% to $2.8B as Apellis Drugs Offset MS Slide
Biogen Q3 2026 earnings: revenue rose 11% to $2.8B, beating forecasts, as Apellis drugs, Spinraza and Leqembi offset MS declines. Guidance edged up.
Warsh Cites Faster Growth, High Inflation as Fed Holds at 3.75%–4%
Fed holds at 3.75%-4% as Warsh cites strong growth, high inflation; 10-year yield tops 5%, December hike odds hit 85%. What it means for Mass. borrowers.